TrialPath
Recruiting

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

NCT07717411 · Hoffmann-La Roche
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
About this study
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
Eligibility criteria
Inclusion Criteria: * Body weight of 150 kg or less * Willingness and ability to complete all aspects of the study for the duration of the study * Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted) * Cognitively and functionally unimpaired as defined by the protocol * Availability of a study partner as defined by the protocol * A plasma pTau217 level consistent with a high likelihood of future clinical progression Exclusion Criteria: * Any evidence of a condition other than AD that may affect cognition, including, but not limited to, frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson disease, corticobasal syndrome, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal lobar degeneration (other than frontotemporal dementia), Huntington disease, normal pressure hydrocephalus, seizure disorder, delirium, or hypoxia * Mild cognitive impairment (MCI; may be referred to as prodromal AD), or any form of dementia * History or presence of clinically significant cerebrovascular disease * History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system (CNS) trauma * History or presence of clinically significant intracranial mass * History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder * History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 12 months of an acute event that is consistent, in the opinion of the PI, with a transient ischemic attack * At risk for suicide in the opinion of the investigator * Substance abuse disorder within 12 months prior to screening (nicotine use is allowed) * Any other medical conditions (e.g., cardiovascular, hepatic, renal disease) which are not stable and adequately controlled or which in the opinion of the investigator could affect the participant's safety in the study or interfere with the study assessments * Uncontrolled hypertension * Impaired hepatic function * History or presence of any clinically significant hematological diseases * Diagnosis of a wet age-related macular degeneration (AMD) * Abnormal thyroid function * Abnormally low serum levels of folic acid or vitamin B12 deficiency that are judged to be clinically significant and/or may impact cognition as per the investigator's judgment * Current HIV, hepatitis B, or hepatitis C infection that has not been adequately treated in the opinion of the investigator * History of malignancy * Any previous administration of active immunotherapy (vaccine) that is being evaluated to prevent or postpone cognitive decline * Any previous or current use of passive immunotherapy (immunoglobulin) or other long-acting biologic agent that is approved or under evaluation or has been evaluated to prevent or postpone cognitive decline * Any other investigational treatment within 5 half-lives or 4 months prior to screening, whichever is longer * Intravenous (IV) or subcutaneous immunoglobulin therapy within 5 half-lives or 4 months prior to baseline whichever is longer * Anticoagulation medications at screening and there should be no plans to initiate any prior to or after randomization * Any treatment with cholinesterase inhibitors * Antipsychotic or neuroleptic medications within 3 months of screening, except as brief treatment for a non-psychiatric indication * Individuals with chronic use of opiates or opioids, benzodiazepines, barbiturates, or hypnotics, antidepressants or medication to treat anxiety should be on a stable dose for at least 8 weeks before baseline * Currently enrolled in an interventional study including those requiring investigational medicinal product (IMP) or involving any type of medical research that may interfere with study cognitive assessments * Residence in a skilled nursing facility such as a convalescent home or long-term care facility
Study design
Enrollment target: 1600 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-10-02
Estimated completion: 2032-09-03
Last updated: 2026-11-06
Interventions
Drug: TrontinemabDrug: Placebo
Primary outcomes
  • • Time to Progression, defined as confirmed Clinical Dementia Rating - Global Score (CDR-GS) > 0 (Baseline up to approximately 6 years)
Sponsor
Hoffmann-La Roche · industry
Contacts & investigators
ContactReference Study ID Number: WN46072 https://forpatients.roche.com · contact · global-roche-genentech-trials@gene.com · 1-888-662-6728
InvestigatorClinical Trials · study_director, Hoffmann-La Roche
All locations (72)
Irvine Center for Clinical ResearchRecruiting
Irvine, California, United States
Healthy Brain ClinicRecruiting
Long Beach, California, United States
Inglewood ClinicalsRecruiting
Los Angeles, California, United States
Oakland ClinicalRecruiting
Oakland, California, United States
Riverside ClinicalRecruiting
Riverside, California, United States
Syrentis Clinical ResearchRecruiting
Santa Ana, California, United States
Cenexel California Neuroscience Research, LLCRecruiting
Sherman Oaks, California, United States
K2 Medical Research, LLCRecruiting
Maitland, Florida, United States
Renstar Medical ResearchRecruiting
Ocala, Florida, United States
Charter Research - Winter Park/OrlandoRecruiting
Orlando, Florida, United States
Conquest Research - Lake NonaRecruiting
Orlando, Florida, United States
Alzheimer's Research and Treatment CenterRecruiting
Stuart, Florida, United States
Charter Research - Lady Lake/The VillagesRecruiting
The Villages, Florida, United States
Alzheimer?s Research and Treatment CenterRecruiting
Wellington, Florida, United States
Conquest Research, LLCRecruiting
Winter Park, Florida, United States
Alzheimer's Research and Treatment Center - ColumbusRecruiting
Columbus, Georgia, United States
Hawaii Pacific NeuroscienceRecruiting
Honolulu, Hawaii, United States
Great Lakes Clinical Trials Chicago d/b/a Flourish Research AndersonvilleRecruiting
Chicago, Illinois, United States
Adams Clinical BostonRecruiting
Boston, Massachusetts, United States
Boston Center for MemoryRecruiting
Newton, Massachusetts, United States
Adams Clinical WatertownRecruiting
Watertown, Massachusetts, United States
Basil ClinicalRecruiting
Laurelton, New York, United States
Sana Research, LLCRecruiting
Arlington, Virginia, United States
National Clinical Research Inc.-RichmondRecruiting
Richmond, Virginia, United States
INECO Neurociencias OronoRecruiting
Rosario, Santa Fe Province, Argentina
Hospital Italiano de Buenos AiresRecruiting
Buenos Aires, Argentina
Royal Prince Alfred HospitalRecruiting
Camperdown, New South Wales, Australia
KaRa Institute of Neurological DiseasesRecruiting
Macquarie Park, New South Wales, Australia
Hospital Moinhos de VentoRecruiting
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clinicas - UFRGSRecruiting
Porto Alegre, Rio Grande do Sul, Brazil
Kelowna Health and Memory Centre Ltd.Recruiting
Kelowna, British Columbia, Canada
Kawartha Regional Memory ClinicRecruiting
Peterborough, Ontario, Canada
Toronto Memory ProgramRecruiting
Toronto, Ontario, Canada
Centricity Research TorontoRecruiting
Toronto, Ontario, Canada
Genge Partners Inc.Recruiting
Montreal, Quebec, Canada
Alpha Recherche CliniqueRecruiting
Québec, Canada
Clínica MEDSRecruiting
Santiago, Chile
The second Affiliated Hospital of Guangzhou Medical UniversityRecruiting
Guangzhou, Guangdong, China
The First Hospital of Hebei Medical UniversityRecruiting
Shijiazhuang, Hebei, China
the First Hospital of Jilin UniversityRecruiting
Changchun, Jilin, China
Yan'an University Xianyang HospitalRecruiting
Xianyang, Shaanxi, China
Peking University First HospitalRecruiting
Beijing, China
Beijing Friendship Hospital Affiliated of Capital University of Medical ScienceRecruiting
Beijing, China
Xuanwu Hospital, Capital Medical UniversityRecruiting
Beijing, China
Fujian Medical University Union HospitalRecruiting
Fuzhou, China
Guangdong Provincial People's HospitalRecruiting
Guangzhou, China
Sir Run Run Shaw Hospital Zhejiang UniversityRecruiting
Hangzhou, China
The Second Affiliated Hospital of Nanchang UniversityRecruiting
Nanchang, China
The Second Affiliated Hospital of Nanjing Medical UniversityRecruiting
Nanjing, China
Nanjing Brain HospitalRecruiting
Nanjing, China
Nanjing First HospitalRecruiting
Nanjing, China
Tongji Hospital of Tongji UniversityRecruiting
Shanghai, China
The Second Affiliated Hospital of Suzhou UniversityRecruiting
Suzhou, China
Shaanxi Provincial People's HospitalRecruiting
Xi'an, China
The First Affiliated Hospital of Xi'an Medical UniversityRecruiting
Xi'an, China
National Center for Geriatrics and GerontologyRecruiting
Aichi, Japan
Kobe University HospitalRecruiting
Hyōgo, Japan
Medical Corporation Asbo Tokyo Asbo ClinicRecruiting
Tokyo, Japan
Clinical Research Hospital TokyoRecruiting
Tokyo, Japan
Tokyo Medical University HospitalRecruiting
Tokyo, Japan
Higashi-Shinjuku ClinicRecruiting
Tokyo, Japan
Tokyo Metropolitan Institute for Geriatrics and GerontologyRecruiting
Tokyo, Japan
National Taiwan University HospitalRecruiting
Taipei, Taiwan
Taipei Veterans General HospitalRecruiting
Taipei, Taiwan
Taipei Medical University ?Shuang Ho HospitalRecruiting
Zhonghe Dist., Taiwan
Scottish Brain SciencesRecruiting
Aberdeen, United Kingdom
Re:Cognition Health BirminghamRecruiting
Birmingham, United Kingdom
Surrey and Borders NHS Foundation TrustRecruiting
Chertsey, United Kingdom
Scottish Brain SciencesRecruiting
Edinburgh, United Kingdom
Re:Cognition Health LondonRecruiting
London, United Kingdom
Charing Cross HospitalRecruiting
London, United Kingdom
Moorgreen HospitalRecruiting
Southampton, United Kingdom
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease · TrialPath